Arcadia Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
RKDA$0.17+3.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,936 | $6,518 |
| Short-term investments | 2,640 | 5,124 |
| Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of September 30, 2024 and December 31, 2023 | 882 | 506 |
| Inventories — current | 835 | 837 |
| Assets held for sale | — | 51 |
| Note receivable — current | 1,827 | — |
| Prepaid expenses and other current assets | 521 | 807 |
| Current assets of discontinued operations — GoodWheat | 70 | 1,129 |
| Total current assets | 10,711 | 14,972 |
| Property and equipment, net | 55 | 70 |
| Right of use asset | 306 | 792 |
| Inventories — noncurrent | — | 196 |
| Intangible assets, net | 39 | 39 |
| Note receivable — noncurrent | 3,966 | — |
| Other noncurrent assets | 164 | 164 |
| Noncurrent assets of discontinued operations — GoodWheat | — | 3,472 |
| Total assets | $15,241 | $19,705 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,692 | $1,910 |
| Amounts due to related parties | 30 | 58 |
| Operating lease liability — current | 346 | 852 |
| Other current liabilities | 260 | 270 |
| Current liabilities of discontinued operations — GoodWheat | — | 500 |
| Total current liabilities | 2,328 | 3,590 |
| Operating lease liability — noncurrent | — | 155 |
| Common stock warrant and option liabilities | 764 | 1,257 |
| Other noncurrent liabilities | 2,000 | 2,000 |
| Total liabilities | 5,092 | 7,002 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value—150,000,000 shares authorized; 1,364,940 and 1,285,337 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 65 | 65 |
| Additional paid-in capital | 284,919 | 284,515 |
| Accumulated other comprehensive income | 117 | 101 |
| Accumulated deficit | (274,814) | (271,840) |
| Total stockholders’ equity | 10,287 | 12,841 |
| Non-controlling interest | (138) | (138) |
| Total stockholders' equity | 10,149 | 12,703 |
| Total liabilities and stockholders’ equity | $15,241 | $19,705 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.